Tumor electric field therapy (TEFT) inhibits glioblastoma progression by suppressing the TGF‐β/SMAD2/3/STAT3/C1R axis to reverse epithelial‐mesenchymal transition (EMT). The gene discussed is C1R; the disease is glioblastoma.